Human T-cell responses to botulinum neurotoxin. Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients

Journal of Neuroimmunology

Volumn 237, Issue 1-2, 2011, Pages 66-72

  Oshima, Minako ^a   Deitiker, Philip R ^a   Jankovic, Joseph ^a   Duane, Drake D ^b   Aoki, K Roger ^c   Atassi, M Z ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Arizona Dystonia Institute   (United States)

^c ALLERGAN INC   (United States)

Author keywords

Botulinum neurotoxin type a and b; Cervical dystonia; Movement disorders; T cell; Tetanus toxin

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; TETANUS TOXIN;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; NEUROTOXINS; T-LYMPHOCYTES; TETANUS TOXIN; YOUNG ADULT;

EID: 80051472909     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.06.005     Document Type: Article

References (40)

1. Aoki K.R. Immunologic and other properties of therapeutic botulinum toxin serotypes. Scientific and Therapeutic Aspects of Botulinum Toxin 2002, 103-113. Lippincott Williams & Wilkins, Philadelphia. M.F. Brin, M. Hallett, J. Jankovic (Eds.).
2. Atassi M.Z. Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking or protein binding sites. Eur. J. Biochem. 1984, 145:1-20.
3. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
4. Atassi M.Z., Oshima M. Structure, activity and immune (T and B cell) recognition of botulinum neurotoxin. Crit. Rev. Immun. 1999, 19:219-260.
5. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 2005, 42:1509-1520.
6. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol. Immunol. 2008, 45:3878-3888. Epub 2008 Aug 3.
7. Brashear A., Lew M., Dykstra D.D. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439-1446.
8. Brin M.F., Comella C.L., Jankovic J., Lai F., Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov. Disord. 2008, 23:1353-1360.
9. Comella C.L., Stebbins G.T., Goetz C.G., Chmura T.A., Bressman S.B., Lang A.E. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov. Disord. 1997, 12:570-575.
10. David C.S., Atassi M.Z. Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. Biol. 1982, 150:97-126.
11. Diamond A., Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J. Cosmet. Dermatol. 2006, 5:169.
12. Dolimbek B.Z., Jankovic J., Atassi M.Z. Cross reaction of tetanus and botulinum neurotoxin A and B and the boosting effect of botulinum neurotoxin A and B on a primary anti-tetanus antibody response. Immunol. Invest. 2002, 31:247-262.
13. Dolimbek G.S., Dolimbek B.Z., Aoki K.R., Atassi M.Z. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol. Invest. 2005, 34:119-142.
14. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44:1029-1041. Epub 2006 May 2.
15. Eisel U., Jarausch W., Goretzki K., Henschen A., Engels J., Weller U., Hudel M., Habermann E., Niemann H. Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J. 1986, 5:2495-2502.
16. Galazka A.M. Tetanus. Module 3: The Immunological Basis for Immunization Series. World Health Organization Expanded Programme on Immunization 1993, 1-22. WHO/EPI/GEN/93.13, WHO, Geneva.
17. Göschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp. Neurol. 1997, 147:96-102.
18. Gui D., Rossi S., Runfola M., Magalini S.C. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment. Pharmacol. Ther. 2003, 18:1-16.
19. Jankovic J. Botulinum Toxin: Clinical Implications of Antigenicity and Immunoresistance. Scientific and Therapeutic Aspects of Botulinum Toxin 2002, 409-415. Lippincott Williams & Wilkins, Philadelphia. M.F. Brin, M. Hallett, J. Jankovic (Eds.).
20. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006, 5:864-872.
21. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009, 54:614-623.
22. Jankovic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
23. Jankovic J., Hunter C., Dolimbek B.Z., Dolimbek G.S., Adler C.H., Brashear A., Comella C.L., Gordon M., Riley D.E., Sethi K., Singer C., Stacy M., Tarsy D., Atassi M.Z. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006, 67:2233-2235.
24. Krieglstein K.G., DasGupta B.R., Henschen A.H. Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Prot. Chem. 1994, 13:49-57.
25. Mahajan S.T., Brubaker L. Botulinum toxin: from life-threatening disease to novel medical therapy. Am. J. Obstet. Gynecol. 2007, 196:7-15.
26. Medication guide for Myobloc® injection issued in 2009.
27. Middlebrook J.L. Cellular mechanism of action of botulinum neurotoxin. J. Toxicol. Toxin Rev. 1986, 5:177-190.
28. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., Jabbari B., Kaufmann H.C., Schurch B., Silberstein S.D., Simpson D.M. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Neurology 2008, 70:1707-1714.
29. Naumann M., Carruthers A., Carruthers J., Aurona S.K., Zafonte R., Abu-Shakra S., Booshoo T., Miller-Messana A., Demos G., James L., Beddingfield F., VanDenburgh A., Chapman A., Brin M.F. Meta-analysis of neutralizing antibody conversion with OnabotulinumtoxinA (BOTOX) across multiple indications. Mov. Disord. 2010, 25:2211-2218.
30. Okuda K., Christadoss P.R., Twining S.S., Atassi M.Z., David C.S. Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J. Immunol. 1978, 121:866-868.
31. Okuda K., Twining S.S., David C.S., Atassi M.Z. Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 1979, 123:182-188.
32. Okuda K., Sakata S., Atassi M.Z., David C.S. Genetic control of the immune response to hen's egg-white lysozyme in mice. I. Antibody and T-lymphocyte proliferative responses to the native protein. J. Immunogenet. 1979, 6:447-452.
33. Oshima M., Pachner A.R., Atassi M.Z. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol. Immunol. 1994, 31:833-843.
34. Oshima M., Hayakari M., Middlebrook J.L., Atassi M.Z. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol. Immunol. 1997, 34:1031-1040.
35. Prescribing information for BOTOX® issued on 10/2010.
36. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
37. Simpson L.L. Peripheral actions of the botulinum toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 153-178. Academic Press, New York. L.L. Simpson (Ed.).
38. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., Jankovic J., Karp B., Ludlow C.L., Miyasaki J.M., Naumann M., So Y. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Neurology 2008, 70:1699-1706.
39. Veronesi R., Cecin H., Corrêa A., Tavares J., Moraes C., Bertoldo O.J. New concepts on tetanus immunization: naturally acquired immunity. J. Hyg. Epidemiol. Microbiol. Immunol. 1975, 19:126-134.
40. Zar J.H. Biostatistical Analysis 1996, Prentice Hall, Englewood Cliffs, New Jersey. Second Edition.